Journal
JOURNAL OF BONE AND MINERAL RESEARCH
Volume 34, Issue 10, Pages 1780-1788Publisher
WILEY
DOI: 10.1002/jbmr.3852
Keywords
CANCER; OSTEOIMMUNOLOGY; OTHER; PRIMARY TUMORS OF BONE AND CARTILAGE; SYSTEMS BIOLOGY - BONE INTERACTORS; THERAPEUTICS
Categories
Funding
- NCI NIH HHS [R21 CA205794] Funding Source: Medline
Ask authors/readers for more resources
Primary malignant bone tumors are rare, occur in all age groups, and include distinct entities such as osteosarcoma, Ewing sarcoma, and chondrosarcoma. Traditional treatment with some combination of chemotherapy, surgery, and radiation has reached the limit of efficacy, with substantial room for improvement in patient outcome. Furthermore, genomic characterization of these tumors reveals a paucity of actionable molecular targets. Against this backdrop, recent advances in cancer immunotherapy represent a silver lining in the treatment of primary bone cancer. Major strategies in cancer immunotherapy include stimulating naturally occurring anti-tumor T cells and adoptive transfer of tumor-specific cytotoxic T cells. Chimeric antigen receptor T cells (CAR-T cells) belong to the latter strategy and are an impressive application of both insights into T cell biology and advances in genetic engineering. In this review, we briefly describe the CAR-T approach and discuss its applications in primary bone tumors. (c) 2019 American Society for Bone and Mineral Research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available